Caribou Biosciences Status
The company raised $30 million of Series B funding in a deal led by Anterra Capital on May 16, 2016, putting the company's pre-money valuation at $113.8 million. Yushan Ventures, Jenny Rooke, Genus (NASDAQ:GGNS), Novartis Venture Funds, BANSEA, F-Prime Capital Partners, Heritage Group, Maverick Ventures (San Francisco) and Pontifax Global Food and Agriculture Technology Fund also participated in this round. The funding will be used to expand the gene editing technology platform and accelerate the use of the application in areas like agriculture, therapeutics, biological research and industrial biotechnology.
Add a review